Fruquintinib: First Global Approval
- 145 Downloads
Fruquintinib (Elunate®) is an orally available, potent and highly selective small molecule inhibitor of VEGFR-1, -2 and -3 that was discovered and developed by Hutchison MediPharma for the treatment of solid tumours. In September 2018, fruquintinib received its first global approval, in China, for use in the treatment of metastatic colorectal cancer (CRC) in patients who have failed at least two prior systemic anti-neoplastic therapies. Fruquintinib is in ongoing phase III clinical development for use in the treatment of advanced NSCLC and advanced gastric cancer. This article summarizes the milestones in the development of fruquintinib leading to this first approval for the treatment of metastatic CRC.
Compliance with Ethical Standards
The preparation of this review was not supported by any external funding.
Conflicts of interest
During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Matt Shirley is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.
- 5.Chi-Med. Chi-Med announces the approval of fruquintinib capsules for previously treated colorectal cancer in China [media release]. 2018. http://www.chi-med.com/wp-content/uploads/2018/09/a180905.pdf. Accessed 27 Sep 2018.
- 6.Chi-Med. Chi-Med initiates fruquintinib U.S. clinical trials [media release]. 2017. http://www.chi-med.com/wp-content/uploads/2017/12/a171215.pdf. Accessed 27 Sep 2018.
- 7.Chi-Med. Cancer therapy collaboration with Lilly [media release]. 2013. http://www.chi-med.com/wp-content/uploads/docArchive/announcements/a131009.pdf. Accessed 27 Sep 2018.
- 8.Ren Y, Sun Q, Long J, et al. Evaluation of fruquintinib, a potent and selective oral VEGFR inhibitor, in combination with targeted therapies or immune checkpoint inhibitors in preclinical tumor models [abstract no. 2089 plus poster]. Cancer Res. 2017;77(13 Suppl):2089.Google Scholar
- 9.Cao J, Zhang J, Peng W, et al. A Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1, -2, and -3 tyrosine kinases in Chinese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2016;78(2):259–69.CrossRefGoogle Scholar
- 12.Li K, Li X, Xia S, et al. Pharmacokinetics of fruquintinib in humans [abstract no. PII-116 plus poster]. Clin Pharmacol Ther. 2018;103 (Suppl S1):S86.Google Scholar